Streetbeat News

Equity Actions

OCUP

Ocuphire Pharma, Inc. (NASDAQ:OCUP) has appointed George Magrath as its new CEO and member of the Board of Directors. Magrath, who has extensive experience in the pharmaceutical industry, succeeds Rick Rodgers, who has been serving as Interim CEO since April 2023. Magrath was previously the CEO of Lexitas Pharmaceutical Services, where he led significant growth and increased revenue. He will lead Ocuphire in advancing the clinical development of its lead retina asset, APX3330.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:24 pm

DERM

JSPR

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has appointed Thomas G. Wiggans, a veteran biopharmaceutical executive, as Chairperson of its Board of Directors. Wiggans has served in senior leadership positions at multiple successful biopharmaceutical companies, including Dermira (NASDAQ:DERM), which was acquired by Eli Lilly in 2020. The current Chairperson, Bill Lis, will retire from the Board in December.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:17 pm

CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT) has appointed Monica Tellado as President, Emerging Markets. Tellado, who previously served as CFO at Heartflow and held various leadership roles at Gilead Sciences, will report to Corcept's CEO and join the company's Executive Team. She will serve as the global commercial lead for therapeutics in metabolism and neurology and oversee pipeline and portfolio planning activities across the company's other therapeutic areas.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:17 pm

SPRO

Spero Therapeutics has announced the appointment of Esther Rajavelu as its new CFO and Chief Business Officer. She will be succeeding Stephen Dipalma, who has been serving as the company's interim CFO since August 1, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:13 pm

MOTS

Motus GI has announced a 1-for-15 reverse stock split, which will begin trading on a split-adjusted basis from November 2.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:04 pm

VTVT

vTv Therapeutics Inc. (NASDAQ:VTVT) has sold all of its common stock in Reneo Pharmaceuticals for approximately $4.4 million. The proceeds will support vTv's preparations for the launch of the cadisegliatin Phase 3 program in type 1 diabetes. vTv remains eligible to receive up to $94.5 million in milestones, as well as royalties on potential sales of products under the Reneo license agreement.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:02 pm

F

GM

TSLA

Tesla CEO Elon Musk has acknowledged room for improvement in the company's deliveries despite its dominance in the EV market. This comes as other major players like General Motors and Ford Motor are scaling down their EV targets. Ford is delaying its $12 billion EV investment and will continue to focus on combustion engine and hybrid vehicles. General Motors has scrapped its plans to develop affordable EVs under $30K with Honda Motor and withdrew its EV production targets.

Portfolio Pulse from Anan Ashraf

November 01, 2023 | 11:36 am

NEPH

Nephros has appointed Judy Krandel as its new Chief Financial Officer (CFO), effective immediately.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 11:36 am

ALIT

Alight, Inc has updated its FY23 revenue forecast to $3.47B-$3.51B, representing a growth of 11% to 12%. The company also expects an adjusted EPS of $0.65-$0.69, up from the prior estimate of $0.62-$0.67. Other projections include adjusted EBITDA of $735M-$750M, BPaaS total contract value bookings of $700M-$900M, and an operating cash flow conversion rate of 45-55%.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 11:34 am

TRMB

Trimble Inc. has announced that its CFO, David Barnes, will retire from the company in May 2024. Phil Sawarynski has been named as his successor.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 11:29 am